Nancy B. Davis

Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer

Karim Fizazi, Johann S. de Bono, Aude Fléchon et al. · European Journal of Cancer · 2011 · 195 citations

Medicine, Oncology, Pharmacotherapy +17

Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma

Nizar M. Tannir, Neeraj Agarwal, Camillo Porta et al. · JAMA Oncology · 2022 · 142 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase II Trial of PS-341 in Patients With Renal Cell Cancer: A University of Chicago Phase II Consortium Study

Nancy B. Davis, David Taber, Rafat Ansari et al. · Journal of Clinical Oncology · 2003 · 141 citations · Full text

Medicine, Oncology, Pharmacology +16

Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer

Matthew D. Galsky, Amir Mortazavi, Matthew I. Milowsky et al. · Journal of Clinical Oncology · 2020 · 133 citations · Full text

Medicine, Oncology, Pharmacology +7

Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study

Moshe Chaim Ornstein, Sumanta K. Pal, Laura S. Wood et al. · The Lancet Oncology · 2019 · 99 citations

Medicine, Oncology, Pharmacology +12